Effects of Milrinone on Neonates after Patent Ductus Arteriosus Ligation: A Retrospective Nationwide Database Study.
Infant
Infant, Newborn
Humans
Ductus Arteriosus, Patent
/ drug therapy
Milrinone
/ therapeutic use
Retrospective Studies
Enterocolitis, Necrotizing
/ epidemiology
Bronchopulmonary Dysplasia
/ epidemiology
Retinopathy of Prematurity
/ complications
Infant, Premature
Cerebral Hemorrhage
/ complications
Ligation
/ adverse effects
Bronchopulmonary dysplasia
Cardiovascular function
Extremely low birth weight infants
Mortality
Patent ductus arteriosus
Journal
Neonatology
ISSN: 1661-7819
Titre abrégé: Neonatology
Pays: Switzerland
ID NLM: 101286577
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
07
2023
accepted:
30
08
2023
medline:
11
12
2023
pubmed:
28
9
2023
entrez:
27
9
2023
Statut:
ppublish
Résumé
Milrinone is administered after patent ductus arteriosus (PDA) ligation to prevent and treat postoperative hemodynamic instability (i.e., postligation cardiac syndrome). We aimed to explore the effectiveness of milrinone on in-hospital outcomes in infants who underwent PDA ligation using a nationwide inpatient database in Japan. Using the Japanese Diagnosis Procedure Combination database, we identified patients who received milrinone after PDA ligation (n = 428) in neonatal intensive care units between July 2010 and March 2021 and those who did not (n = 3,392). We conducted a 1:4 propensity score-matched analysis with adjustment for background characteristics (e.g., gestational age, birth weight, comorbidities, preoperative treatments, and hospital background) to compare morbidities (bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, and retinopathy of prematurity), mortality, total hospitalization costs, and other outcomes. For sensitivity analysis, we performed an overlap propensity score-weighted analysis. In-hospital morbidity, bronchopulmonary dysplasia, intraventricular hemorrhage, and necrotizing enterocolitis occurred in 58%, 48%, 9.5%, and 7.1% of patients, respectively; the in-hospital mortality was 5.4%. After 1:4 propensity score matching, no significant difference was observed regarding mortality (7.1 vs. 5.7%), in-hospital morbidity (55 vs. 50%), bronchopulmonary dysplasia (44 vs. 41%), intraventricular hemorrhage (7.8 vs. 9.1%), necrotizing enterocolitis (8.5 vs. 8.9%), retinopathy of prematurity (21 vs. 22%), or total hospitalization costs (median: approximately 86,000 vs. 82,000 US dollars) between milrinone users (n = 425) and nonusers (n = 1,698). Sensitivity analyses yielded consistent results. Milrinone use after PDA ligation was not associated with improved in-hospital outcomes, such as mortality and morbidity.
Identifiants
pubmed: 37757762
pii: 000533958
doi: 10.1159/000533958
pmc: PMC10711761
doi:
Substances chimiques
Milrinone
JU9YAX04C7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
751-759Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
J Pediatr. 2015 Jun;166(6):1488-92
pubmed: 25882876
Pediatrics. 2009 Jan;123(1):e138-44
pubmed: 19117835
Pediatr Pulmonol. 2021 Oct;56(10):3250-3257
pubmed: 34288596
N Engl J Med. 2000 Sep 7;343(10):728-30
pubmed: 10974138
J Perinatol. 2021 Aug;41(8):1783-1796
pubmed: 34012057
Pediatr Int. 2016 Nov;58(11):1171-1175
pubmed: 27062220
Pediatrics. 2020 Nov;146(5):
pubmed: 33093140
J Epidemiol. 2017 Oct;27(10):476-482
pubmed: 28142051
J Pediatr. 2014 Jun;164(6):1449-55.e1
pubmed: 24636853
J Perinatol. 2008 Dec;28(12):803-10
pubmed: 18615091
J Pediatr. 2007 Jun;150(6):597-602
pubmed: 17517241
Eur J Pediatr. 2011 Jan;170(1):115-9
pubmed: 20848128
J Invest Surg. 2008 May-Jun;21(3):133-8
pubmed: 18569433
J Pediatr. 2017 Oct;189:105-112
pubmed: 28600155
J Psychiatr Res. 2021 Jan;133:101-105
pubmed: 33338731
Breast Cancer Res Treat. 2022 Oct;195(3):289-299
pubmed: 35917051
J Perinatol. 2018 May;38(5):537-542
pubmed: 29453434
Neonatology. 2017;111(1):8-11
pubmed: 27490706
J Pediatr. 2014 Jul;165(1):46-52.e1
pubmed: 24814414
Arch Dis Child Fetal Neonatal Ed. 2005 May;90(3):F235-9
pubmed: 15846015
Clin Perinatol. 2012 Mar;39(1):221-38
pubmed: 22341548
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
Surg Today. 2022 Oct;52(10):1484-1490
pubmed: 35552817
JAMA. 2020 Jun 16;323(23):2417-2418
pubmed: 32369102
Pediatr Crit Care Med. 2019 Jul;20(7):621-629
pubmed: 30664589
BMC Health Serv Res. 2021 Oct 18;21(1):1116
pubmed: 34663302
BMC Pediatr. 2014 Aug 08;14:199
pubmed: 25102958
J Am Soc Echocardiogr. 2012 Oct;25(10):1058-67
pubmed: 22889993
Am J Perinatol. 2022 Jan;39(2):204-215
pubmed: 32781477
J Matern Fetal Neonatal Med. 2021 Apr;34(7):1028-1033
pubmed: 31117870
JAMA Pediatr. 2017 May 1;171(5):443-449
pubmed: 28264088
BMJ. 2019 Oct 23;367:l5657
pubmed: 31645336
J Thorac Cardiovasc Surg. 2016 Aug;152(2):498-504
pubmed: 27174516
Transl Pediatr. 2019 Jul;8(3):199-211
pubmed: 31413954
J Pediatr. 2012 Apr;160(4):584-589.e1
pubmed: 22050874
N Engl J Med. 2016 Dec 8;375(23):2293-2297
pubmed: 27959688